Vaccinex reports 100% recurrence-free at 24 months in Stage III melanoma triple combination

VACCINEX, INC.

Triple combo (pepinemab+nivolumab+ipilimumab) achieved 100% recurrence-free survival at 24 months vs <40% for dual combos.
LAG-3 upregulation identified as resistance mechanism to pepinemab+nivolumab; rationale for triple with LAG-3 inhibitor.
Pepinemab combinations induced tertiary lymphoid structures and CD26hi CD4+ T cells in tumors.
Phase 1/2 trial enrolling for pepinemab+trastuzumab+DC vaccine in HER2+ metastatic breast cancer (NCT05378464).
Interim analysis of KEYNOTE-B84 (pepinemab+KEYTRUDA in HNSCC) expected in Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.